{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:51Z","timestamp":1786984311769,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajoc.2022.101528","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T11:23:04Z","timestamp":1649503384000},"page":"101528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Dupilumab-associated cicatrizing ocular disease"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-823X","authenticated-orcid":false,"given":"Amit K.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9392-4998","authenticated-orcid":false,"given":"Scott G.","family":"Hauswirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren G.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5209","authenticated-orcid":false,"given":"Sophie D.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-6767","authenticated-orcid":false,"given":"Alan G.","family":"Palestine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ajoc.2022.101528_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2022.101528_bib2","doi-asserted-by":"crossref","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond). Jan 28 2021;doi:10.1038\/s41433-020-01379-9.","DOI":"10.1101\/2020.06.16.20124909"},{"key":"10.1016\/j.ajoc.2022.101528_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"12","key":"10.1016\/j.ajoc.2022.101528_bib4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"10086","key":"10.1016\/j.ajoc.2022.101528_bib5","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101528_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther."},{"issue":"6","key":"10.1016\/j.ajoc.2022.101528_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"10.1016\/j.ajoc.2022.101528_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101528_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol."},{"issue":"1","key":"10.1016\/j.ajoc.2022.101528_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol."}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622002742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:01:20Z","timestamp":1762527680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622002742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":10,"alternative-id":["S2451993622002742"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101528","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab-associated cicatrizing ocular disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101528"}}